文献速递乳腺MR

三阴性乳腺癌患者新辅助化疗期间肿瘤进展及生存结局的预测

Prediction of Tumor Progression During Neoadjuvant Chemotherapy and Survival Outcome in Patients With Triple-Negative Breast Cancer.
PubMed 文献 · Korean J Radiol · 2023-01-01

本研究为单中心回顾性研究,纳入2010至2019年间接受新辅助化疗的252例三阴性乳腺癌女性,分析临床、病理及MRI变量与化疗期间进展性疾病(PD)及无远处转移生存(DMFS)的关联。按2:1随机分为开发集和验证集,分别用逻辑回归和Cox比例风险回归构建PD和DMFS预测模型并验证。临床-病理-MRI模型(含皮下水肿)预测PD的AUC在验证集为0.69,高于临床-病理模型的0.54(P=0.017);但MRI未独立贡献于DMFS预测,DMFS模型验证集Harrell's C-index为0.86。

要点

  • MRI见皮下水肿是三阴性乳腺癌新辅助化疗期间PD的独立预测因素(OR 30.6,P=0.004)。
  • 临床-病理-MRI模型预测PD的AUC在验证集为0.69,高于临床-病理模型的0.54(P=0.017)。
  • MRI未独立贡献于DMFS预测;DMFS模型验证集Harrell's C-index为0.86。

核心结论

  • 临床-病理-MRI模型考虑MRI所见皮下水肿,预测PD优于临床-病理模型;但MRI未独立贡献于DMFS预测。

研究设计与样本

  • 单中心回顾性研究,纳入252例接受新辅助化疗的三阴性乳腺癌女性(2010-2019年),按2:1随机分为开发集168例和验证集84例,由两名放射科医师分析化疗前MRI,采用逻辑回归和Cox比例风险回归分别构建PD和DMFS预测模型并验证。

关键影像表现/征象

  • MRI所见皮下水肿在开发集中与PD独立相关(OR 30.6,P=0.004)。
  • 化生性组织学与PD独立相关(OR 8.0,P=0.032)。
  • Ki-67指数与PD独立相关(OR 1.02,P=0.044)。

诊断标准与关键数值

  • 临床-病理-MRI模型预测PD的AUC在验证集为0.69,临床-病理模型为0.54(P=0.017)。
  • 乳腺和淋巴结均残留病变与DMFS独立相关(HR 6.0,P=0.005)。
  • 脉管侵犯与DMFS独立相关(HR 3.3,P<0.001)。
  • 由上述病理变量构成的DMFS模型在验证集Harrell's C-index为0.86。

临床应用与阅片要点

  • 阅片时可关注化疗前MRI上的皮下水肿,该征象与PD独立相关(OR 30.6)。
  • 临床-病理-MRI模型预测PD的AUC在验证集为0.69,高于临床-病理模型的0.54(P=0.017)。
  • MRI未独立贡献于DMFS预测,DMFS模型验证集Harrell's C-index为0.86。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the association of clinical, pathologic, and magnetic resonance imaging (MRI) variables with progressive disease (PD) during neoadjuvant chemotherapy (NAC) and distant metastasis-free survival (DMFS) in patients with triple-negative breast cancer (TNBC).

MATERIALS AND METHODS: This single-center retrospective study included 252 women with TNBC who underwent NAC between 2010 and 2019. Clinical, pathologic, and treatment data were collected. Two radiologists analyzed the pre-NAC MRI. After random allocation to the development and validation sets in a 2:1 ratio, we developed models to predict PD and DMFS using logistic regression and Cox proportional hazard regression, respectively, and validated them.

RESULTS: Among the 252 patients (age, 48.3 ± 10.7 years; 168 in the development set; 84 in the validation set), PD was occurred in 17 patients and 9 patients in the development and validation sets, respectively. In the clinical-pathologic-MRI model, the metaplastic histology (odds ratio [OR], 8.0; P = 0.032), Ki-67 index (OR, 1.02; P = 0.044), and subcutaneous edema (OR, 30.6; P = 0.004) were independently associated with PD in the development set. The clinical-pathologic-MRI model showed a higher area under the receiver-operating characteristic curve (AUC) than the clinical-pathologic model (AUC: 0.69 vs. 0.54; P = 0.017) for predicting PD in the validation set. Distant metastases occurred in 49 patients and 18 patients in the development and validation sets, respectively. Residual disease in both the breast and lymph nodes (hazard ratio [HR], 6.0; P = 0.005) and the presence of lymphovascular invasion (HR, 3.3; P < 0.001) were independently associated with DMFS. The model consisting of these pathologic variables showed a Harrell's C-index of 0.86 in the validation set.

CONCLUSION: The clinical-pathologic-MRI model, which considered subcutaneous edema observed using MRI, performed better than the clinical-pathologic model for predicting PD. However, MRI did not independently contribute to the prediction of DMFS.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Yoen H, Kim SY, Lee DW, et al. Prediction of Tumor Progression During Neoadjuvant Chemotherapy and Survival Outcome in Patients With Triple-Negative Breast Cancer. Korean J Radiol. 2023. PMID: 37404105. doi:10.3348/kjr.2022.0974

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。